

Regd. Office :
'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: March 1, 2016</p>	
<p>Re.: Press Release.</p>	


Dear Sir / Madam,

We enclose herewith a copy of press release dated March 1, 2016 under the title “**Zydus Cadila has received final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP from its formulation manufacturing facility at Baddi**”. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,
For **Cadila Healthcare Limited**


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus receives final approval from the USFDA for Glyburide and Metformin Hcl Tablets USP

The formulations manufacturing facility at Baddi will produce the drug for the US market

Ahmedabad, 01 March 2016

Zydus Cadila has received the final approval from the USFDA to market Glyburide and Metformin Hcl Tablets USP in strengths of 1.25/250, 2.5/500 and 5/500 mg. The drug falls in the anti-diabetics segment and the group's formulations manufacturing site at Baddi will be producing the drug for the US market.

The group now has 103 approvals and has so far filed over 280 ANDAs since the commencement of the filing process in FY 2003-04.
